References
- Kantarjian H, Sawyers C, Hochhaus A, Guilholt F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenic responses to imatinib mesylate in chronic myelocytic leukemia. N Engl J Med 2002; 346: 645–652
- Ma C X, Hobday T J, Jett J R. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc 2003; 76: 1578–1579
- Isshiki I, Yamaguchi K, Okamoto S. Interstitial pneumonitis during imatinib therapy. Br J Haematol 2004; 125: 420
- Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Espe'rou G, et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol 2002; 20: 4271–4272
- Rosado M F, Donna E, Ahn Y S. Challenging problems in advanced malignancy: case 3. Imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol 2003; 21: 3171–3173
- Akoun G M, Cadranel J, Rosenow E C, 3rd. Bronchoalveolar lavage cell data in drug-induced pneumonitis. Allerg Immunol 1991; 23: 245–252
- Appel S, Balabanov S, Brummendorf T H, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 2005; 23: 1082–1088